Treatment of PTLD

Post-Transplant Lymphoproliferative Disorders

Volumn , Issue , 2010, Pages 117-131

  Webber, Steven A ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890239435     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-01653-0_9     Document Type: Chapter

References (51)

1. Rosenwald A, Wright G, Chan WC, et al. The lymphoma/leukemia molecular profiling project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-47
2. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583-7
3. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6:569-76
4. Hurwitz M, Desai DM, Cox KL, et al. Complete immunosuppression withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant. 2004;8:267-72
5. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367:233-9
6. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076-88
7. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation. 2004;78:1676-82
8. Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B and chemotherapy for posttransplant lymphoproliferative disorder. Transplantation. 2008;86:215-22
9. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63:4472-80
10. Vaysberg M, Balatoni CE, Nepomuceno RR, et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation. 2007;83:1114-21
11. Traum AZ, Rodig NM, Pilichowska ME, et al. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients. Pediatr Transplant. 2006;10:505-12
12. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus induced B-cell lymphoma after renal transplantation. N Eng J Med. 1982;306:913-18
13. Prichard MN, Hartline CB, Harden EA, et al. Inhibition of herpes virus replication by hexadecyloxypropyl esters of purine-and pyramidine-based phosphonomethoxyethyl nucleoside phosphonates. Antimicrob Agents Chemother. 2008;52:4326-30
14. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother. 2005;49:3724-33
15. Perrine SP, Hermine O, Small T, et al. A phase I/II trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus associated lymphoid malignancies. Blood. 2007;109:2571-8
16. Ghosh SK, Forman LW, Akinsheye I, et al. Short discontinuous exposure to butyrate effectively sensitizes latently EBV-infected cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis. 2007;38:57-65
17. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66:1770-9
18. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin [letter]. N Engl J Med. 1988; 318:1334
19. Haddad E, Paczesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood. 2001;97:1590-7
20. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virusinfected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 1994;84:972-84
21. Fisher A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451-6
22. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11(Suppl 1):113-6
23. Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104:1661-7
24. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chemeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation. 2005;80:1692-8
25. Knoop C, Kentos A, Remmelink M, et al. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin Transplant. 2006;20:179-87
26. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3053-7
27. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901-6
28. Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007;86:599-607
29. Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single agent rituximab. Transplantation. 2007;84:1708-12
30. Webber S, Harmon W, Faro A, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience from a registry and from a prospective clinical trial. Blood. 2004;104:213a
31. Salvado B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005;5:566-72
32. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23:6481-8
33. Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res. 2003;9(10 Pt 2):3945S-52
34. Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica. 2007;92:273-4
35. Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol. 2006;134:602-12
36. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333-40
37. Trappe R, Riess H, Babel N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation. 2007;83:912-8
38. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for post-transplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry. Transplant Proc. 2005;37: 956-7
39. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet. 1995;345:9-13
40. Swinnen LJ. Immune-cell treatment of Epstein-Barr-virus-associated lymphoproliferative disorders. Best Pract Res Clin Haematol. 2006;19:839-47
41. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant. 2005;5:1415-22
42. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942-9
43. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T cell therapy for EBV-positive posttransplant lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123-31
44. Comoli P, Ginevri F, Maccario R, et al. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV seronegative children. Am J Transplant. 2006;6:2169-76
45. Metes D, Storkus W, Zeevi A, et al. Ex vivo generation of effective Epstein-Barr Virus (EBV)-specific CD8+ cytotoxic T cells from peripheral blood of immunocompetent EBV-seronegative individuals. Transplantation. 2000;70:1507-15
46. Buell JF, Gross TG, Hanaway MJ, et al. Post-transplant lymphoproliferative disorder: signifi-cance of central nervous system involvement. Transplant Proc. 2005;37:954-5
47. Castellano-Sanchez AA,Li S, Qian J, et al. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol. 2004;121:246-53
48. Bianchi E, Pascual M, Nicod M, et al. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation. 2008;85:707-12
49. Sebelin-Wulf K, Nguyen TD, Oertel S, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ recipients with PTLD. Transpl Immunol. 2007;17:203-10
50. Guppy AE, Rawlings E, Madrigal JA, et al. A quantitative assay for Epstein-Barr virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat post-transplant lymphoproliferative disease. Transplantation. 2007;84: 1534-9
51. Baudouin V, Dehee A, Pedron-Grossetete B, et al. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. Transplantation. 2004;77:1706-13